Cordell W. Hull Joins Gilead Sciences Board of Directors.Business Editors/Medical & Health Writers FOSTER CITY, Calif.--(BW HealthWire)--April 18, 2001 Gilead Sciences Gilead Sciences NASDAQ: GILD is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. , Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : GILD) announced today that Cordell W. Hull has been appointed to the company's Board of Directors. Mr. Hull also will chair the Audit Committee of the Board of Directors. Mr. Hull, 67, is the co-founder, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of InfrastructureWorld, Inc., a business-to-business portal for the global infrastructure community. Prior to founding InfrastructureWorld, Inc., he has held the positions of Chairman of Bechtel Enterprises, Chief Financial Officer of Bechtel Group and President of American Express American Express (NYSE: AXP), sometimes known as "AmEx" or "Amex", is a diversified global financial services company, headquartered in New York City. The company is best known for its credit card, charge card and traveler's cheque businesses. Company's merchant banking operations in London. Mr. Hull serves as a Director of Darby Overseas Investments, Ltd., Bechtel Group, Inc., Bechtel Enterprises and the Fremont Group Fremont Group is a private equity group based in San Francisco, California, USA. It was formerly known as Bechtel Investments, reflecting its ownership by the Bechtel family. . "We are pleased to welcome Cordell to the Gilead Sciences Board of Directors," said James M. Denny, Chairman of Gilead's Board of Directors. "His broad business experience and financial expertise will be of great benefit as Gilead moves toward profitability with the anticipated launch of tenofovir DF, Gilead's investigational treatment for HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. infection." Gilead Sciences Gilead Sciences, Inc., headquartered in Foster City, CA, is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. Gilead discovers, develops, manufactures and commercializes proprietary therapeutics for challenging infectious diseases infectious diseases: see communicable diseases. (viral, fungal and bacterial infections) and cancer. Gilead maintains research, development or manufacturing facilities in Foster City, CA; Boulder, CO; San Dimas, CA; Cambridge, UK and Dublin, Ireland and sales and marketing organizations in the United States, Europe and Australia. For more information on Gilead Sciences, please visit the company's Web site at www.gilead.com or call the Gilead Corporate Communications Department at 1-800-GILEAD-5 (1-800-445-3235). |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion